Hypertension, Cholesterol, and Aspirin with Cost Info

Total Page：16

File Type：pdf, Size：1020Kb

Hypertension, Cholesterol, and Aspirin with Cost Info

Diabetes & Your Health High Blood Pressure & Diabetes Aspirin & Did you know as many as two out of three adults with Heart Health diabetes have high blood pressure? High blood pressure Studies have shown is a serious problem. It can raise your chances of stroke, that taking a low- heart attack, eye problems, and kidney disease. dose aspirin every Many people do not know they have high blood pressure day can lower the because they do not have any symptoms. That is why it risk for heart attack is often called “the silent killer.” and stroke. The only way to know if you have high blood pressure is Aspirin can help to have it checked. If you have diabetes, you should those who are at high have your blood pressure checked every time you see risk of heart attack, the doctor. People with diabetes should try to keep their such as people who blood pressure lower than 130 over 80. have diabetes or high blood pressure. Cholesterol & Diabetes Aspirin can also help Keeping your cholesterol and other blood fats, called lipids, under control can people with diabetes help you prevent diabetes problems. Cholesterol and blood lipids that are too who have already high can lead to heart attack and stroke. Many people with diabetes have had a heart attack or problems with their cholesterol and other lipid levels. a stroke, or who have heart disease. You will not know that your cholesterol and blood lipids are at dangerous levels unless you have a blood test to have them checked. Everyone with diabetes Taking an aspirin a should have cholesterol and other lipid levels checked at least once per year. day is not safe for Some people will need to have them checked more often. everyone. Ask your doctor if taking aspirin would be right for How Can I Control My Blood Pressure & Cholesterol? you. • Quit smoking. Do not use any tobacco products. For more information, • If you take blood pressure medicine or cholesterol medicine, be sure to take it like your doctor told you. contact: • Enjoy regular physical activity. SoonerCare Disease • Lose weight if you are overweight. Management Services (405) 522-6205 • Eat a healthy diet with lots of vegetables. • Eat a diet that is low in salt, saturated fat, and cholesterol. (800) 522-0114 • Have your cholesterol and other blood lipids checked at least once per year. or talk to your doctor. Sources: American Diabetes Associat ion, American Heart Association This publication is authorized by the Oklahoma Health Care Authority in accordance with state and federal regulations and printed by the University of Oklahoma Printing Services. Cost of the printing was $475.00 for 15,000 copies. OHCA is in compliance with Title VI and Title VII of the 1964 Civil Rights Act and the Rehabilitation Act of 1973. Copies have been deposited with the Oklahoma Department of Libraries Clearinghouse. The Oklahoma Health Care Author- ity does not discriminate on the basis of race, color, national origin, sex, religion, age or disability in employment or the provision of services. Order additional copies on the OHCA Web site www.okhca.org. .

Copy Link

Recommended publications

Hypertension: Putting the Pressure on the Silent Killer
HYPERTENSION: PUTTING THE PRESSURE ON THE SILENT KILLER MAY 2016 TABLEHypertension: putting OF the CONTENTS pressure on the silent killer Table of contents UNDERSTANDING HYPERTENSION AND THE LINK TO CARDIOVASCULAR DISEASE 2 Understanding hypertension and the link to cardiovascular disease THEThe social SOCIAL and economic AND impact ECONOMIC of hypertension IMPACT OF HYPERTENSION 3 Diagnosing and treating hypertension – what is out there? DIAGNOSINGChallenges to tackling hypertension AND TREATING HYPERTENSION – WHAT IS OUT THERE? 6 Opportunities and focus areas for policymakers CHALLENGES TO TACKLING HYPERTENSION 9 OPPORTUNITIES AND FOCUS AREAS FOR POLICYMAKERS 15 HYPERTENSION: PUTTING THE PRESSURE ON THE SILENT KILLER UNDERSTANDING HYPERTENSION AND THE LINK TO CARDIOVASCULAR DISEASE Cardiovascular disease (CVD), or heart disease, is the number one cause of death in the world. 80% of deaths due to CVD occur in countries and poor communities where health systems are weak, and CVD accounts for nearly half of the estimated US$500 billion annual lost economic output associated with noncommunicable diseases (NCDs) in low-income and middle-income countries. In 2012, CVD killed 17.5 million people – the equivalent of every 3 in 10 deaths.1 Of these 17 million deaths a year, over half – 9.4 million - are caused by complications in hypertension, also commonly referred to as raised or high blood pressure2. Hypertension is a risk factor for coronary heart disease and the single most important risk factor for stroke - it is responsible for at least 45% of deaths due to heart disease, and at least 51% of deaths due to stroke. High blood pressure is defined as a systolic blood pressure at or above 140 mmHg and/or a diastolic blood pressure at or above 90 mmHg.
[Show full text]
Hypertension and Coronary Heart Disease
Journal of Human Hypertension (2002) 16 (Suppl 1), S61–S63 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh Hypertension and coronary heart disease E Escobar University of Chile, Santiago, Chile The association of hypertension and coronary heart atherosclerosis, damage of arterial territories other than disease is a frequent one. There are several patho- the coronary one, and of the extension and severity of physiologic mechanisms which link both diseases. coronary artery involvement. It is important to empha- Hypertension induces endothelial dysfunction, exacer- sise that complications and mortality of patients suffer- bates the atherosclerotic process and it contributes to ing a myocardial infarction are greater in hypertensive make the atherosclerotic plaque more unstable. Left patients. Treatment should be aimed to achieve optimal ventricular hypertrophy, which is the usual complication values of blood pressure, and all the strategies to treat of hypertension, promotes a decrease of ‘coronary coronary heart disease should be considered on an indi- reserve’ and increases myocardial oxygen demand, vidual basis. both mechanisms contributing to myocardial ischaemia. Journal of Human Hypertension (2002) 16 (Suppl 1), S61– From a clinical point of view hypertensive patients S63. DOI: 10.1038/sj/jhh/1001345 should have a complete evaluation of risk factors for Keywords: hypertension; hypertrophy; coronary heart disease There is a strong and frequent association between arterial hypertension.8 Hypertension is frequently arterial hypertension and coronary heart disease associated to metabolic disorders, such as insulin (CHD). In the PROCAM study, in men between 40 resistance with hyperinsulinaemia and dyslipidae- and 66 years of age, the prevalence of hypertension mia, which are additional risk factors of atheroscler- in patients who had a myocardial infarction was osis.9 14/1000 men in a follow-up of 4 years.
[Show full text]
Major Clinical Considerations for Secondary Hypertension And
& Experim l e ca n i t in a l l C Journal of Clinical and Experimental C f a o r d l i a o Thevenard et al., J Clin Exp Cardiolog 2018, 9:11 n l o r g u y o Cardiology DOI: 10.4172/2155-9880.1000616 J ISSN: 2155-9880 Review Article Open Access Major Clinical Considerations for Secondary Hypertension and Treatment Challenges: Systematic Review Gabriela Thevenard1, Nathalia Bordin Dal-Prá1 and Idiberto José Zotarelli Filho2* 1Santa Casa de Misericordia Hospital, São Paulo, Brazil 2Department of scientific production, Street Ipiranga, São José do Rio Preto, São Paulo, Brazil *Corresponding author: Idiberto José Zotarelli Filho, Department of scientific production, Street Ipiranga, São José do Rio Preto, São Paulo, Brazil, Tel: +5517981666537; E-mail: [email protected] Received date: October 30, 2018; Accepted date: November 23, 2018; Published date: November 30, 2018 Copyright: ©2018 Thevenard G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Introduction: In this context, secondary arterial hypertension (SH) is defined as an increase in systemic arterial pressure (SAP) due to an identifiable cause. Only 5 to 10% of patients suffering from hypertension have a secondary form, while the vast majorities have essential hypertension. Objective: This study aimed to describe, through a systematic review, the main considerations on secondary hypertension, presenting its clinical data and main causes, as well as presenting the types of treatments according to the literary results.
[Show full text]
Pulmonary Hypertension ______
Pulmonary Hypertension _________________________________________ What is it? High blood pressure in the arteries that supply the lungs is called pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The blood pressure measured by a cuff on your arm isn’t directly related to the pressure in your lungs. The blood vessels that supply the lungs constrict and their walls thicken, so they can’t carry as much blood. As in a kinked garden hose, pressure builds up and backs up. The heart works harder, trying to force the blood through. If the pressure is high enough, eventually the heart can’t keep up, and less blood can circulate through the lungs to pick up oxygen. Patients then become tired, dizzy and short of breath. If a pre-existing disease triggered the PH, doctors call it secondary pulmonary hypertension. That’s because it’s secondary to another problem, such as a left heart or lung disorder. However, congenital heart disease can cause PH that’s similar to PH when the cause isn’t known, i.e., idiopathic or unexplained pulmonary arterial hypertension. In this case, the PAH is considered pulmonary arterial hypertension associated with congenital heart disease, such as associated with a VSD or ASD (either repaired or unrepaired). The problem is due to scarring in the small arteries in the lung. It’s important to repair congenital heart problems (when possible) before permanent pulmonary hypertensive changes develop. Intracardiac left-to-right shunts (such as a ventricular or atrial septal defect, a hole in the wall between the two ventricles or atria) can cause too much blood flow through the lungs.
[Show full text]
Uncontrolled Hypertension and Associated Factors Among Hypertensive Adults in Bale Zone Public Hospitals, Ethiopia Feyissa Lemessa1* and Miressa Lamessa2
ISSN: 2474-3690 Lemessa and Lemessa. J Hypertens Manag 2021, 7:057 DOI: 10.23937/2474-3690/1510057 Volume 7 | Issue 1 Journal of Open Access Hypertension and Management ORIGINAL RESEARCH Uncontrolled Hypertension and Associated Factors among Hypertensive Adults in Bale Zone Public Hospitals, Ethiopia Feyissa Lemessa1* and Miressa Lamessa2 1 Department of Nursing, St. Paul’s Hospital Millennium Medical College, Addis Ababa, Ethiopia Check for 2Department of Emergency and Critical Care, St. Paul’s Hospital Millennium Medical College, Addis Ababa, updates Ethiopia *Corresponding author: Feyissa Lemessa Jinfessa, Department of Nursing, St. Paul’s Hospital Millennium Medical College, Addis Ababa, Ethiopia, Tel : +251-920-405-878 Abstract Conclusion: The prevalence of uncontrolled hypertension was high at the study area among patients with hyperten- Background: Although blood pressure control has tremen- sion. Being overweight and lack of awareness on Hyperten- dous public health benefit, and has effective treatments, the sion i.e. poor knowledge on hypertension management can global rate of uncontrolled blood pressure remains high. In result in hypertension-related complications. Hence, Con- sub-Saharan Africa including Ethiopia uncontrolled blood tinuous health education on lifestyle practices and hyper- pressure resulted in a significant morbidity and mortality. tension-related complications in each follow-up visit highly Unfortunately, uncontrolled hypertension among adult hy- recommended. pertensive patients remains unclear and has been inade- quately studied in Ethiopia, in the study area in particular. Keywords Objective of the study: This study assessed uncontrolled Uncontrolled hypertension, Self-care practice, Bale, Ethiopia hypertension and associated factors among adult hyperten- sive patients on follow up clinics in Bale Zone Public Hospi- tals, Ethiopia, 2017.
[Show full text]
Hypertension and Hypotension
19/06/2018 Hypertension • Definitions: • WHO 140/90 • Westmead: calling criteria Hypertension and • If untreated 50% die of cardiovascular disease • 33% get a stroke Hypotension • 10% will develop renal failure Dr Giles Miller Hypertension • Causes • Essential • Renal • Endocrine • Neurogenic • Psychogenic • Miscellaneous 1 19/06/2018 Hypertension Hypertension treatments • Patterns • GTN patch • Hyperdynamic • Hydralazine • Vasoconstricted • B‐blockers • End Organ Damage • Ca channel • Cardiac • Diuretics • Eyes • ACEI • Renal • Angiotensin II blockers • Cerebral • Central acting alpha agonists Case Studies ‐ 1 Case 1 Needs to be reviewed but not a high priority • 78 yr old male • Past History • Admitted with UTI and delirium. Normally lives at home with • Mild dementia daughter as carer. • Hypertension ‐ Normally well controlled with BP 130/80 • Chronic renal failure (Cr 180) Always check the Medications! • Nurse calls you BP 168/92 at 10am on sat morning. • Medications • Diuretics, ACEI. • What are you going to do? • Missed daily dose of antiHT. 2 19/06/2018 Case Studies ‐ 2 Case 2 • Usual BP 150/90. • 56yr old lady with ESRF • On multiple antiHT • Dialysis 3 times a week via left AVF • ‐metoprolol, felodipine. • Had been drinking more recently due to some hot weather. Went • Nurse calls as BP prior to dialysis is 210/100 over usual fluid restriction. Weight up by 5kg You would always check with the renal physician/med reg first • What are you going to do? • Prazocin would be a typical drug to use in this circumstance Case Studies ‐ 3 Case 3 • Pre‐eclampsia definition: SBP >140, DBP >90 with renal involvement • Pregnant lady, 34 weeks. causing proteinuria.
[Show full text]
Pulmonary Hypertension Could Be a Risk for Deep Vein Thrombosis in Lower Extremities After Joint Replacement Surgery
Pulmonary hypertension could be a risk for deep vein thrombosis in lower extremities after joint replacement surgery Paerhati Rexiti1 Minawaer Wutiku2 Wuhuzi Wulamu1 FengZhou Bai1 Li Cao1 1. Department of Orthopaedics, The First Affiliation Hospital of Xinjiang Medical University, Urumqi, China. 2. Department of Sonography, Fourth Affiliated Hospital of Xinjiang Medical University, Urumqi, China. http://dx.doi.org/10.1590/1806-9282.65.7.946 SUMMARY A background of Pulmonary Hypertension (PH) indicates a progressive elevation of pulmonary vascular resistance, leading to overfilling, elevation of venous pressure, congestion in various organs, and edema in the venous system. This study aimed to investigate whether PH is a risk factor for deep vein thrombosis (DVT) of the lower extremities after hip and knee replacement surgery. METHODS: A total of 238 patients who received joint replacement of lower extremities in our department of orthopedics from January 2009 to January 2012 were examined by echocardiography and Color Doppler flow imaging (CDFI) of the lower extremities. Based on pulmonary artery pressure (PAP), the patients were divided into a normal PAP group (n=214) and PH group (n=24). All the patients were re-examined by CDFI during post-operative care. RESULTS: Among the 238 patients, 18 had DVT in the lower extremities after the operation. DVT total incidence rate was 7.56% (18/238). In the PH group, 11 patients had DVT (45.83%, 11/24), but in the normal PAP group, only 7 had DVT (3.27%, 7/214). The incidence of DVT was significantly lower in the normal PAP group than in the PH group (P<0.01).
[Show full text]
High Cholesterol and High Blood Pressure What You Should Know
High Cholesterol and High Blood Pressure what you should know Vital information about: • cholesterol • risk factors • lifestyle modification • treatment options Charles J. Glueck, MD, and Dean J. Kereiakes, MD, FACC This book may discuss pharmaceutical products and/or uses of products that have not been approved by the United States Food and Drug Administration. For approved product information, please consult the manufacturer’s complete prescribing information for the product. Provided as an Educational Service by The Christ Hospital Health Network 1 Copyright © 2019 by Robertson & Fisher Publishing Company. First Edition. All rights reserved. Published by Robertson & Fisher Publishing Company, Cincinnati, Ohio Authors: Charles J. Glueck, MD, and Dean J. Kereiakes, MD, FACC Contributing Editors: Ian J. Sarembock, MD, FACC, FAHA, FSCAI; Paul Ribisl, PhD; Rona Wharton, MEd, RD, LD; and, Douglas Wetherill, MS. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without the prior written permission of the publisher. Requests to the publisher for permission should be directed to the Permissions Department, Robertson & Fisher Publishing Company at [email protected]. The information contained in this book is not intended to serve as a replacement for professional medical advice. Any use of the information in this book is at the reader’s discretion. The authors and the publisher specifically disclaim any and all liability arising directly or indirectly from the use or application of any information contained in this book.
[Show full text]
Secondary Hypertension: Discovering the Underlying Cause LESLEY CHARLES, MD; JEAN TRISCOTT, MD; and BONNIE DOBBS, Phd University of Alberta, Edmonton, Alberta, Canada
This is a corrected version of the article that appeared in print. Secondary Hypertension: Discovering the Underlying Cause LESLEY CHARLES, MD; JEAN TRISCOTT, MD; and BONNIE DOBBS, PhD University of Alberta, Edmonton, Alberta, Canada Most patients with hypertension have no clear etiology and are classified as having primary hypertension. However, 5% to 10% of these patients may have secondary hypertension, which indicates an underlying and potentially revers- ible cause. The prevalence and potential etiologies of secondary hypertension vary by age. The most common causes in children are renal parenchymal disease and coarctation of the aorta. In adults 65 years and older, atherosclerotic renal artery stenosis, renal failure, and hypothyroidism are common causes. Secondary hypertension should be considered in the presence of suggestive symptoms and signs, such as severe or resistant hypertension, age of onset younger than 30 years (especially before puberty), malignant or accelerated hypertension, and an acute rise in blood pressure from previously stable readings. Additionally, renovascular hypertension should be considered in patients with an increase in serum creatinine of at least 50% occurring within one week of initiating angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy; severe hypertension and a unilateral smaller kidney or dif- ference in kidney size greater than 1.5 cm; or recurrent flash pulmonary edema. Other underlying causes of secondary hypertension include hyperaldosteronism, obstructive sleep apnea, pheochromocytoma, Cushing syndrome, thyroid disease, coarctation of the aorta, and use of certain medications. (Am Fam Physician. 2017;96(7):453-461. Copyright © 2017 American Academy of Family Physicians.) CME This clinical content ypertension is common, affect- hypertension, onset before 30 years of age conforms to AAFP criteria ing nearly 30% of U.S.
[Show full text]
Hypertension Control
HYPERTENSION CONTROL U. S. Department of Health and Human Services Health Resources and Services Administration Hypertension Control Contents Quality Measure: Breast Cancer Screening Measure Description ................................................................................................................. 1 Part 1: Introduction ................................................................................................................. 1 Performance Measurement: Hypertension Control ............................................................... 2 Part 2: Characteristics for Success: Hypertension Control................................................ 5 Part 3: Implementation of Quality Measure: Hypertension Control ............................... 11 Critical Pathway for Hypertension Control .......................................................................... 12 Factors That Impact the Critical Pathway ............................................................................. 16 Data Infrastructure: Hypertension Control .......................................................................... 20 Implementation: Hypertension Control ............................................................................... 21 Part 4: Improvement Strategies: Hypertension Control................................................... 25 What Changes Can an Organization Make? ......................................................................... 26 How Can an Organization Make Those Changes? ..............................................................
[Show full text]
JNC 7 Express the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
National High Blood Pressure Education Program JNC 7 Express The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute JNC 7 Express The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure This work was supported entirely by the National Heart, Lung, and Blood Institute. The Executive Committee, writing teams, and reviewers served as volunteers without remuneration. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute National High Blood Pressure Education Program NIH Publication No. 03-5233 December 2003 Chair Aram V. Chobanian, M.D. (Boston University Medical Center, Boston, MA) Executive Committee George L. Bakris, M.D. (Rush Presbyterian-St. Luke’s Medical Center, Chicago, IL); Henry R. Black, M.D. (Rush Presbyterian-St. Luke’s Medical Center, Chicago, IL); William C. Cushman, M.D. (Veterans Affairs Medical Center, Memphis, TN); Lee A. Green, M.D., M.P.H. (University of Michigan, Ann Arbor, MI); Joseph L. Izzo, Jr., M.D. (State University of New York at Buffalo School of Medicine, Buffalo, NY); Daniel W. Jones, M.D. (University of Mississippi Medical Center, Jackson, MS); Barry J. Materson, M.D., M.B.A. (University of Miami, Miami, FL); Suzanne Oparil, M.D. (University of Alabama at Birmingham, Birmingham, AL); Jackson T. Wright, Jr., M.D., Ph.D. (Case Western Reserve University, Cleveland, OH) Executive Secretary Edward J.
[Show full text]
Complication Prevention for Patients with Hypertension a Noncommunicable Disease Education Manual for Primary Health Care Professionals and Patients
Complication prevention for patients with hypertension A noncommunicable disease education manual for primary health care professionals and patients Complication prevention for patients with hypertension A noncommunicable disease education manual for primary health care professionals and patients The Noncommunicable Disease Education Manual for Primary Health Care Professionals and Patients results from the contributions and hard work of many people. Its development was led by Dr Hai-Rim Shin, Coordinator, and Dr Warrick Junsuk Kim, Medical Officer, of the Noncommunicable Diseases and Health Promotion unit at the WHO Regional Office for the Western Pacific (WHO/WPRO/NCD) in Manila, Philippines. WHO graciously acknowledges the intellectual contributions of Dr Jung-jin Cho, Co-director, Community-based Primary Care Project Committee and Professor, Department of Family Medicine, Hallym University Sacred Heart Dongtan Hospital, Republic of Korea; Dr Hyejin Lee, Volunteer, WHO/WPRO/NCD (currently PhD candidate, Department of Family Medicine, Seoul National University, Republic of Korea); Ms Saki Narita, Volunteer, WHO/WPRO/NCD (currently PhD candidate, Department of Global Health Policy, Graduate School of Medicine, University of Tokyo, Japan); and Mr Byung Ki Kwon, Technical Officer, WHO/WPRO/NCD (currently Director, Division of Health Promotion, Ministry of Health and Welfare, Republic of Korea). Many thanks to Dr Albert Domingo, Dr Sonia McCarthy, Ms Marie Clem Carlos, Dr Katrin Engelhardt, Mr Kelvin Khow Chuan Heng and Dr Roberto Andres Ruiz from the WHO Regional Office for the Western Pacific and Dr Ma. Charina Benedicto, Physician-in-Charge, Bagong Barangay Health Center & Lying-in Clinic, Pandacan, Manila, Philippines for reviewing the draft publication. Financial support for this publication was received from the Korea Centers for Disease Control and Prevention, Republic of Korea.
[Show full text]